ASPECTS OF SARCOPENIA SYNDROME IN ONCOLOGICAL PRACTICE: DIAGNOSIS AND TREATMENT
Keywords:
Abstract
Sarcopenia is diagnosed in 20-70% of patients with advanced neoplasms and is associated with a number of negative consequences. At the same time, this condition rarely comes to the attention of practicing oncologists, including due to diagnostic difficulties. Correcting sarcopenia requires a multidisciplinary approach, including optimal nutrition with adequate protein intake, micronutrients, and aerobic and strength-training exercise.
References
Guide to Clinical Nutrition. Ed. V.M. Lufta, St. Petersburg, 2016, 484 p. 4.
Baracos VE, Relman T, Mourtzakis M, et al. Body composition in patients with nonsmall lung cancer: a contemporary view of cancer cachexia with the use of computed tomography image analysis. Am. J. Clin. Nutr. 2010; 91(4):1133S1137S. 5.
Bischoff-Ferrari HA. Relevance of vitamin D in muscle health. Rev. Endocr. Metab. Discord. 2012; 13: 71–77. 6.
Chapman I. Weight loss in older persons. Medical clinics of North America. 2011; 95(3):579–93. 7.
Cho KM, Park H, Oh DY, et al. Skeletal muscle depletion predicts survival of patients with advanced biliary tract cancer undergoing palliative chemotherapy.Oncotarget.2017; 8(45):79441–79452. 8.
Choi Y, Oh DY, Kim TY. Skeletal muscle depletion predicts the prognosis of patients with advanced pancreatic cancer undergoing palliative chemotherapy. Independent of BMI. PLoS One. 2015; 10 (10): e0139749. 9.
Cruz-Jentoft AJ, Baeyens JP, Bauer JM et al. Sarcopenia: European consensus on definition and diagnosis: report of the European working group on sarcopenia in older people. Age Aging. 2010; 39 (4): 412–23. 10.
Cushen SJ, Power DG, Ryan AM, Nutrition assessment in oncology. Top. Clin. Nutr. 2015; 30 (1): 103–19. eleven.
Drummond MJ, Rasmussen BB. Leucine-enriched nutrients and the regulation of mTOR signaling and human skeletal muscle protein synthesis. Curr. Opin. Clin. Nutr. Metab. Care. 2008; 11: 222–226. 12.
Ferrando AA, Sheffield-Moore M, Yeckel CW, et al. Testosterone administration to older man improves muscle function: molecular and physiological mechanisms. Am.J. Physiol Endocrinol Metab. 2002; 282:E601–607. 13.
Ferrucci L, Penninx BW, Volpano S, et al. Change in muscle strength explains accelerated decline in physical function in older women with high IL6 serum levels. J. Am. Geriatr, Soc. 2002; 50: 1947–1954. 14.
Fielding RA, Vellas B, Evans WJ, et al. Sarcopenia: an undiagnosed condition in older adults—current consensus definition: prevalence, etiology, and consequences. International Working Group on Sarcopenia. J. Am. Med. Dir. Assoc. 2011; 12: 249–256. 15.
Gonzales MC, Pastore CA, Orlandi SP, et al. Obesity paradox in cancer: new insights provided by body composition. Am J Clin Nutr. 2014; 99:999–1005. 16.
Goodpaster BH, Carlson CL, Visser M, et al. Attenuation of skeletal muscle and strength in the elderly: the health ABC study. J. Appl. Physiol. 2001; 90:2157–2165. 17.
Jansen I, Shepard DS, Katzmarzyk PT, et al. The healthcare costs of sarcopenia in the United States. J. Am. Geriatr. Soc. 2004; 52:80–85. 18.
Kovacheva EL, Hikim AP, Shen R, et al. Testosterone supplementation reverses sarcopenia in aging through regulation of myoststin, c-Jun NH2-terminal kinase, Notch, and Akt signaling pathways. Endocrinology. 2010; 151:628–638. 19.
Kubrak C, Olson K, Jha N, et al. Clinical determinants of weight loss in patients receiving radiation and chemoradiation for head and neck cancer: A prospective longitudinal view. Head Neck. 2013; 35: pp. 695–703. 20.
Kurk SA, Peeters PHM, Dorresteijn B, et al. Evolution of skeletal muscle mass (SMM) during palliative systemic in metastatic colorectal cancer (mCRC) patients participating in the randomized phase 3 CAIRO3 study // Abstract ESMO 2016. Copenhagen, Denmark, 2016. 21.
Malafarina V, Uriz-Otano F, Iniesta R, et al. Sarcopenia in the elderly: diagnosis, physiopathology and treatment. Maturitas.2012; 71: 109–114. 22.
Malmstrom TK, Morley JE. SARC-F: a simple questionnaire to rapidly diagnose sarcopenia. J. Am. Med. Dir. Assoc. 2013; 14(8):531–553. 23.
Martin L., Birdsell L., Macdonald N., et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J. Clin. Oncol, 2013; 31(12):1539–1547. 24.
Melton LJ, 3rd. Khosla S, Crowson CS. Epidemiology of sarcopenia. J. Am. Geriatr, Soc. 2000; 48: 625–630. 25.
Messinger-Rapport B, Thomas D., Gammack H., et al. Clinical update on nursing home medicine: 2009. J. Am. Med. Dir. Association. 2009; 10: 530–53. 26.
Montero-Odasso M, Duque G. Vitamin D in the aging musculoskeletal system: An authentic strength preserving hormone. Mol. Aspects. Med. 2005. 26; 203–219. 27.
Morley JE, Argiles JM, Evans WJ, et al. Society for Sarcopenia, Cachexia, Wasting Disease. Nutritional recommendations for the management of sarcopenia. J. Am. Med. Dir. Association. 2010; 11:391–396. 28.
Muller MJ, Wang Z, Heymsfield SB, et al. Advances in the understanding of specific metabolic rates of major organs and tissues in humans. Curr. Opin. Clin. Nutr. Metab. Care. 2013; 16:501–508. 29.
Muscaritoli M., Anker SD, Argiles J. et al. Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by Special Interest Groups (SIG) “cachexia-anorexia in chronic wasting diseases” and “nutrition in geriatrics”. Clin. Nutr. 2010. Vol. 29, No. 2. P. 154–159. thirty.
Philippou A, Maridaki M, Halapas A, et al. The role of the insulin-like growth factor-I (IGF-I) in skeletal muscle physiology. In Vivo. 2007; 21:45–54. 31.
Prado CM, Baracos VE, McCargar LJ, et al. Body composition as an independent determinant of 5-fluoracil-based chemotherapy toxicity. Clin. Cancer.Res. 2007; 13(1). 3264–3268. 32.
Prado CM, Lieffers JR, McCargar LJ, et al. Prevalence and clinical implications of sarcopenic obesity in patients solid tumors of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol. 2008; 29(2). 154–159. 33.
Prado CM, Antoun S, Sawyer MB. Two faces of drug therapy in cancer: drug-related lean tissue loss and its adverse consequences to survival and toxicity. Curr. Opin. Clin. Nutr. Metab. Care. 2011; 14 (3): 250–254. 34.
Rizzoli R, Reginster JY, Arnal JF, et al. Quality of life in sarcopenia and frailty. Calcif Tissue Int. Springer. 2013. DOI 10.1007/ s00223–013–9759-y. 35.
Rolland Y, Onder G, Morley J, et al. Current and future pharmacological treatment of sarcopenia. Clinics in Geriatric Medicine. 2011; 27:423–447. 36.
Rosenberg IH. Sarcopenia: origins and clinical relevance. Clin. Geriatr. Med. 2011; 27. 337–339. 37.
Roubenoff, Hughes VA. Sarcopenia: current concepts. J. Gerontol. A. Biol. Sci Med. Sci. 2000; 55: M716-M724. 38.
Sakuma K., Yamaguchi A. Molecular mechanisms in aging and current strategies to counteract sarcopenia. Curr Aging Sci. 2010; 3: 90–101. 39.
Scott D, Blizzard L, Fell J, et al. The epidemiology of sarcopenia in community living older adults: what role does lifestyle play? J. Cachexia. Sarcopenia. Muscle 2010; 2: 125–134. 40.
Shakhanova Sh. Shakhnoza, Rakhimov M. Nodir. Aspects of sarcopenia syndrome in oncological practice: diagnosis and treatment (literature review) // Journal of Biomedicine and Practice. 2023, vol. 8, issue 3, pp. 406-417
Shachar S, Williams G, Muss H, Nishijima T. Prognostic value of sarcopenia in adults with solid tumors: A meta-analysis and systematic review. Eur J Cancer. 2016 Apr; 57:58–67. doi: 10.1016/j.ejca.2015.12.030. Epub 2016 Feb 13. Review.
Sharma P, Zargar-Shoshtari K, Caracciolo JT, Fishman M, Poch MA, Pow-Sang J, Sexton WJ, Spiess PE. Sarcopenia as a predictor of overall survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. Urol. Oncol. 2015; 33: 339.e17–23. 42.
Short KR, Nair KS. The effect of age on protein metabolism. Curr. Opin. Clin. Nutr. Metab. Care. 2000; 3:39–44. 43.
Short KR, Vittone JL, Bigelow JL et al. Age and aerobic exercise training effects on whole body and muscle protein metabolism. Am.J. Physiol. Endocrinol. Metab. 2004; 286:E92-E101. 44.
Sinha-Hikim I, Cornford M, Gaytan H, et al. Effects of testosterone supplementation on skeletal muscle fiber hypertrophy and satellite cells in community-dwelling older man. J. Clin. Endocrinol. Metab. 2006; 91:3024–3033.
Stenholm S, Harris TB, Rantanen T, et al. Sarcopenic obesity: definition, cause and consequences. Curr. Opin. Clin. Nutr. Metab. Care. 2008; 11: 693–700. 46. Rakhimov M. Nodir, Tulanov T. Begzod, Shakhanova Sh. Shakhnoza, Aslsnova M. Lobar. Pathogenetic aspects of cancer anorexia// Journal of Biomedicine and Practice. 2023, vol. 8, issue 4, pp.192-201
Tieland M, Kirks ML, van der Zwaluw N, et al. Protein supplementation increases muscle mass gain during prolonged resistance-type exercise training in frail elderly people: a randomized, double-blind, placebo-controlled trial. J. Am. Med. Dir. Association. 2012; 13(8):713–719. 47.
Verdijk LB, Kooman R, Schaart G, et al. Satellite cell content in specifically reduced in type II skeletal muscle fibers in the elderly. Am. J. Physiol. Endocrinol. Metab. 2007; 2902: E151-E157. 48.
Wagners AJ, Conboy IM. Cellular and molecular signatures of muscle regeneration: current concepts and controversies in adult myogenesis. Cell. 2005; 122:659–667. 49.
Waters DL, Baumgartner RN, Garry PJ. Advantages of dietary, exercise-related, and therapeutic interventions to prevent and treat sarcopenia in adult patients: an update. Clin. Interv. Aging. 2010; 5:259–270
